The excess in 2 5 mm follicles seen at ovarian ultrasonography is tightly associated to the follicular arrest of the polycystic ovary syndrome

Similar documents
DEFINING THE POLYCYSTIC ovary syndrome (PCOS)

ORIGINAL ARTICLE Reproductive endocrinology. Submitted on February 4, 2011; resubmitted on April 29, 2011; accepted on May 9, 2011

The relationship of serum anti- Mullerian hormone with polycystic ovarian morphology and polycystic ovary syndrome: a prospective cohort study

Revisiting the ovarian volume as a diagnostic criterion for polycystic ovaries

Original Investigation. 94 Endocrine Oncology and Metabolism. Jovanovska et al

Lille II; and b Laboratory of Endocrinology, C.H.R.U. and Universite de Lille II, Lille, France

Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes

METABOLIC RISK MARKERS IN WOMEN WITH POLYCYSTIC OVARIAN MORPHOLOGY

ROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU)

S. AMH in PCOS Research Insights beyond a Diagnostic Marker

Ultrasound examination of polycystic ovaries: is it worth counting the follicles?

Differentiation between polycystic ovary syndrome and polycystic ovarian morphology by means of an anti-müllerian hormone cutoff value

The Egyptian Journal of Hospital Medicine (January 2018) Vol. 70 (8), Page

The prevalence of polycystic ovary syndrome in Iranian women based on different diagnostic criteria

Department of Obstetrics and Gynecology, Benha Faculty of Medicine, Benha University, Egypt

Polycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018

Gonadotrophin treatment in patients with Polycystic Ovary Syndrome

ANTI-MÜLLERIAN HORMONE (AMH) AS A USEFUL MARKER IN DIAGNOSIS OF POLYCYSTIC OVARY SYNDROME

Endocrine control of female reproductive function

Overview of Reproductive Endocrinology

AMH and PCOS phenotypes. Miro Šimun Alebić, Nataša Stojanović, Alain Duhamel, Dedier DewaIly

Senior resident 5 lll rd year P.G. student

3. Metformin therapy for PCOS

Can high serum anti-müllerian hormone levels predict the phenotypes of polycystic ovary syndrome (PCOS) and metabolic disturbances in PCOS patients?

Clinical and biochemical characteristics of polycystic ovary syndrome in Korean women

In Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome

JMSCR Vol 05 Issue 05 Page May 2017

Introduction. Luciano G. Nardo 1,4, Allen P. Yates 2, Stephen A. Roberts 3, Phil Pemberton 2, and Ian Laing 2

Nitasha Garg 1 Harkiran Kaur Khaira. About the Author

Polycystic ovarian syndrome: Are radiology departments contributing to the misdiagnosis?

Metformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment

WHY NEW DIAGNOSTIC CRITERIA FOR DIFFERENT PCOS PHENOTYPES ARE URGENTLY NEEDED

Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study

X/06/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 91(1):2 6 Copyright 2006 by The Endocrine Society doi: /jc.

Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks

PCOS What s new in Diagnosis & Treatment?

Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a large-scale Chinese population

Determining the insulin resistance rate in Polycystic Ovary Syndrome patients (PCOs)

Polycystic Ovarian Syndrome. Heidi Hallonquist, MD Concord Hospital Concord Obstetrics and Gynecology

Comparison of anti-mullerian hormone and antral follicle count for assessment of ovarian reserve

Clinical Profile Polycystic Ovarian Syndrome Cases

clinical outcome and hormone profiles before and after laparoscopic electroincision of the ovaries in women with polycystic ovary syndrome

Polycystic Ovarian Syndrome: Is It Time to Rename PCOS to HA-PODS?

Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks. Kate D. Schoyer, M.D. May 6, 2016

Dr Stella Milsom. Endocrinologist Fertility Associates Auckland. 12:30-12:40 When Puberty is PCO

The role of AMH in anovulation associated with PCOS: a hypothesis

Prevalence of polycystic ovarian syndrome in the Buraimi region of Oman

lbt lab tests t Conrolled Ovarian Hyperstimulation Dr Soheila Ansaripour

Antim ullerian hormone and polycystic ovary syndrome

Clinical and biochemical presentation of polycystic ovary syndrome in women between the ages of 20 and 40

Metformin Therapy Decreases Hyperandrogenism and Ovarian Volume in Women with Polycystic Ovary Syndrome

Investigation of adrenal functions in patients with idiopathic hyperandrogenemia

Serum Vascular Endothelial Growth Factor in Polycystic Ovary Syndrome and its Relation to Ovarian Drilling

Prevalence and hormonal profile of polycystic ovary syndrome in young Kashmiri women presenting with hirsutism: A hospital based study

Prevalence of Anovulation in Subfertile Women in Kerbala 2012, A descriptive Cross-Sectional Study

REVIEW. Polycystic Ovary Syndrome (PCOS), Diagnostic Criteria, and AMH. Majid Bani Mohammad 1, Abbas Majdi Seghinsara 2 * Abstract.

Can Sex hormone Binding Globulin Considered as a Predictor of Response to Pharmacological Treatment in Women with Polycystic Ovary Syndrome?

Female androgen profiles by MS for PCOS patients. CS Ho APCCMS 2010, Hong Kong 14 January 2010

Relationship between Energy Expenditure Related Factors and Oxidative Stress in Follicular Fluid

New PCOS guidelines: What s relevant to general practice

Original Research Article

Is polycystic ovary syndrome an exception for reproductive aging?

'The effect of weight loss on anti-müiierian hormone levels in overweight and obese women with

Diagnostic Performance of Serum Total Testosterone for Japanese Patients with Polycystic Ovary Syndrome

THYROID PROFILE IN POLYCYSTIC OVARIAN SYNDROME Sudhanshu Sekhara Nanda 1, Subhalaxmi Dash 2, Ashok Behera 3, Bharati Mishra 4

Female Reproductive Physiology. Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF

Assessment of theca cell function prior to controlled ovarian stimulation: the predictive value of serum basal/stimulated steroid levels

Reproductive Health in Non Alcoolic Fatty Liver Disease (NAFLD)

Female Reproductive Endocrinology

Polycystic ovary syndrome

Polycystic Ovary Syndrome (PCOS):

Serum anti-mullerian hormone levels during controlled ovarian hyperstimulation in women with polycystic ovaries with and without hyperandrogenism

Polycystic Ovarian Syndrome (PCOS) LOGO

Serum müllerian-inhibiting substance levels in adolescent girls with normal menstrual cycles or with polycystic ovary syndrome

Follicle dynamics and anovulation in polycystic ovary syndrome

Epidemiological correlates among women with Polycystic ovary syndrome in South India

Comparative Evaluation of Diagnostic Efficacy of Serum. Anti-Müllerian Hormone and Ultrasound in Polycystic Ovarian Syndrome

Polycystic Ovary Syndrome

Anti-Mullerian Hormone as a Predictive Factor in Assisted Reproductive Technique of Polycystic Ovary Syndrome Patients

ROLE OF METFORMIN IN POLYCYSTIC OVARIAN SYNDROME

JMSCR Vol 06 Issue 09 Page September 2018

Polycystic Ovary Disease: A Common Endocrine Disorder in Women

Correlation of Anti-Mullerian Hormone with clinical, hormonal and ultrasonographic parameters in PCOS and normo-ovulatory women

CARDIOVASCULAR EVENTS IN POLYCYSTIC OVARY SYNDROME

The Relation of Serum Anti-Mullerian Hormone with Polycystic Ovary Syndrome: Correlation with Clinical and Hormonal Parameters

Study of clinical presentation in cases of Polycystic Ovarian Syndrome in rural population

Association between Anti-Mullerian Hormone and Ovarian Response and Pregnancy in Polycystic Ovary Syndrome Patients

Reproductive Testing: Less is More G. Wright Bates, Jr., M.D. Professor and Director Reproductive Endocrinology and Infertility Objectives

Anti-mullerian and androgens hormones in women with polycystic ovary syndrome undergoing IVF/ICSI

Cam type Femoroacetabular Impingement associated with Marker for Hyperandrogenism in Women

Thomas M. Barber*, John A. H. Wass*, Mark I. McCarthy* and Stephen Franks

Increased Anti-Müllerian Hormone Serum Concentrations in Prepubertal Daughters of Women with Polycystic Ovary Syndrome

Diagnostic features of polycystic ovary syndrome

Dr. Ernesto Bosch Instituto Valenciano de Infertilidad Valencia, Spain. Declared no potential conflict of interest

BJMHR British Journal of Medical and Health Research Journal home page:

Polycystic Ovary Syndrome

PCOS and Obesity DUB is better treated by OCPs

Reproductive FSH. Analyte Information

Objectives 06/21/18 STILL A PLACE FOR PILLS DON T IVF EVERYTHING. Clomiphene citrate and Letrozole. Infertility Case Studies. Unexplained Infertility

Addressing Practice Gaps in PCOS

Transcription:

Human Reproduction Vol.22, No.6 pp. 1562 1566, 2007 Advance Access publication on April 20, 2007 doi:10.1093/humrep/dem060 The excess in 2 5 mm follicles seen at ovarian ultrasonography is tightly associated to the follicular arrest of the polycystic ovary syndrome Didier Dewailly 1,4, Sophie Catteau-Jonard 1, Anne-Céline Reyss 1, Catherine Maunoury- Lefebvre 1, Edouard Poncelet 2 and Pascal Pigny 3 1 Department of Endocrine Gynaecology and Reproductive Medicine, Hôpital Jeanne de Flandre, C.H.R.U., 59037 Lille, France; 2 Department of Radiology, Hôpital Jeanne de Flandre, C.H.R.U., 59037 Lille, France; 3 Laboratory of Endocrinology, Parc Eurasanté, C.H.R.U., 59037 Lille, France 4 Correspondence address. Tel: 33-3-20-44-69-03; Fax: 33-3-20-44-64-07; E-mail: ddewailly@chru-lille.fr BACKGROUND: We previously hypothesized that the excess of 2 5 mm follicles seen at ovarian ultrasonography might be involved in the follicular arrest (FA) of polycystic ovary syndrome (PCOS), independently from the main putative contributors of FA, namely hyperandrogenism and hyperinsulinism. METHODS: A multivariate statistical analysis was applied retrospectively to clinical, biological and ultrasound data that were consecutively collected during 5 years in 457 patients with polycystic ovaries and in 188 age-matched non-hyperandrogenic and regularly cycling controls without PCO at ultrasound. RESULTS: Stepwise discriminant analysis indicated that in PCOS the 2 5 mm follicle number (FN) gave the strongest correlation to severity of the FA, followed by age and then by fasting insulin level. The other variables [waist circumference (WC), 6 9 mm FN, serum testosterone, FSH, LH and ovarian area] were rejected by the analysis. Multiple linear regression indicated a significant and independent negative relationship between the 2 5 and 6 9 mm FN in the PCOS (r 520.186, P < 0.01) and control groups (r520.281, P<0.01). In PCOS only, the 6 9 mm FN was negatively and independently related to the WC (r520.108, P<0.05). CONCLUSIONS: The size of the 2 5 mm follicle pool is an independent and important contributor to the FA of PCOS. This result could be explained by an exaggerated physiological inhibitory effect from this pool on the terminal follicle growth. The metabolic derangement of PCOS that also contributes to the FA would act through a different mechanism. Keywords: androgens; anovulation; follicular arrest; insulin; polycystic ovary syndrome Introduction Polycystic ovary syndrome (PCOS) is the main cause of anovulatory infertility in women (Franks, 2003). Oligo-anovulation (OA) results from ovarian follicle abnormalities that are thought to be 2-fold (Dewailly et al., 2003; Jonard and Dewailly, 2004). First, in all patients, early follicular growth is excessive, up to the step of follicles becoming sensitive to FSH (i.e. 2 5 mm in diameter). Secondly, the selection of one follicle from the increased pool of selectable follicles (i.e. 6 9 mm in diameter) and its further maturation to a dominant follicle under LH influence does not occur. This second abnormality in the folliculogenesis is named the follicular arrest (FA) and explains the ovulatory disorder of PCOS. Although the FA has not received yet a clear and unanimous explanation, hyperinsulinism (HI) and/or insulin resistance (IR) are considered as important, but not exclusive, contributors to this abnormality (Franks et al., 1998). Furthermore, FA does not always occur in patients with PCOS since some of them do ovulate monthly (Franks et al., 1998; Carmina and Lobo, 2001). In contrast, the excess of small follicles appears as the salient and constant feature of PCO. Pathological studies have shown that the pool of growing primary and secondary follicles is 2 3-fold that of normal ovaries while the pool of primordial follicle is normal (Hughesdon, 1982; Webber et al., 2003). With regard to the important intra-ovarian effects of androgens on the small follicle growth (Vendola et al., 1998; Weil et al., 1998), the hyperandrogenism (HA) of PCOS is designated as the main culprit for this follicle excess (Jonard and Dewailly, 2004). However, evidence for this is mainly experimental, based on animal studies (Vendola et al., 1998; Weil et al., 1998). Little clinical data documenting such a phenomenon is available in women with PCOS. Nevertheless, in a previous study using a selective follicular counting by ultrasound 1562 # The Author 2007. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Follicle excess and follicular arrest in PCOS (i.e. counting separately the 2 5 and 6 9 mm follicles), we reported that the 2 5 mm follicle number (FN) was positively correlated to the serum testosterone and androstenedione levels in patients with PCOS, all three parameters being in excess in comparison to controls (Jonard et al., 2003a). In contrast, we also showed in this previous study that the proportion of larger (6 9 mm) antral follicles, relative to the 2 5 mm FN, was much less than in control women. Further, in a subsequent preliminary study (Jonard et al., 2003b), we observed a negative and significant correlation between the two follicle ranges. This may reflect an impaired transition from the 2 5 to 6 9 mm follicle stage and suggests that the excess of 2 5 mm follicles in PCOS could exert an inhibitory effect on further follicular growth. This study was designed to revisit this preliminary data and to analyse whether the contribution of the excess of 2 5 mm follicles to the FA of PCOS was direct, or indirect through other known contributors of follicular derangement in PCOS, such as HA and/or HI (Franks et al., 1998). Patients and Methods This study was approved by the Institutional Review Board of the University Hospital of Lille. All patients and controls gave an informed consent before their inclusion in this study. Data were obtained from a database including clinical, hormonal and ultrasound features that were consecutively recorded between 2000 and 2005 in patients referred to our department for HA and/or OA, as previously reported (Dewailly et al., 2006). Patient population Controls The control population consisted of 188 women who were referred to our department for IVF because of tubal and/or male infertility. Exclusion criteria were a history of menstrual disturbances (i.e. cycle length either,25 days or.35 days), hirsutism, abnormal serum level of prolactin or androgens (i.e. serum testosterone above 0.7 ng/ml), PCO at ultrasonography and hormonal treatment during the 3 months before the study. Patients with PCOS Four hundred and fifty-seven women were selected for this study. The diagnosis of PCOS was based on the association of at least two of the three following criteria according to the Rotterdam classification (The Rotterdam ESHRE/ASRMsponsored PCOS Consensus Workshop Group, 2004): (i) ovulatory disturbances, mainly oligomenorrhoea or amenorrhoea; (ii) HA as defined either clinically by hirsutism (modified Ferriman and Gallwey score.8) or severe acne/seborrhoea, and biologically by a testosterone serum level.0.7 ng/ml and (iii) more than 12 follicles in the 2 9 mm range in each ovary at ultrasonography and/or an ovarian volume higher than 10 ml. Amenorrhoea, oligomenorrhoea or regular cycles were defined as no menses during.3 months,,8 menses in the preceding year or cycle length between 25 and 35 days, respectively. Investigation procedures Blood sampling was performed in the early follicular phase, between 8.00 and 9.00 AM, between day 2 and day 7 after the last menstrual period both in PCOS patients and in controls. In PCOS patients, the last menstrual period was either spontaneous or induced by the administration of didrogesterone (10 mg/day for 7 days). Ultrasound examination was performed with a 7-MHz transvaginal transducer (Logic 400 General Electric, Milwaukee, WI, USA), the same day as blood sampling. Ultrasound measurements were taken in real time, according to a standardized protocol allowing counting separately the 2 5 and 6 9 mm follicles, as previously described (Jonard et al., 2003a). The ovarian area was measured by outlining the ovarian picture on a longitudinal plane, as previously described (Jonard et al., 2003a). Any patient with at least one follicle with a diameter greater than 9 mm or a serum estradiol level above 80 pg/ml was excluded from the study. Hormone immunoassays LH and FSH were measured using chemiluminescent two sites immunoassays on a multi-parameter system (Axsym, Abbott Laboratories, Rungis, France), while testosterone was measured in duplicate using a radioimmunoassay (Coat-a-count, total testosterone kit) provided by Diagnostic Products Corporation (La Garenne Colombes, France). Fasting serum insulin levels were measured in duplicate by an immunoradiometric assay (Bi-Insulin IRMA Pasteur, Bio-Rad, Marnes la Coquette, France) that uses two monoclonal anti-insulin antibodies. Intra- and inter-assay coefficients of variation for the insulin assay were,3.8 and 7.5%, respectively as previously described (Pigny et al., 2003). Results are expressed as miu/l in terms of the World Health Organization 66/304 reference insulin preparation. Statistical methods Comparisons between two independent groups were performed using the non-parametric Mann Whitney test. One-factor analysis of variance (ANOVA) was used for comparisons between PCOS subgroups with post hoc Bonferroni s correction for 2 2 comparisons between each group. A stepwise discriminant analysis was applied to the set of variables that differed significantly by ANOVA between PCOS subgroups. Significant and independent relationships between variables were evaluated by multiple linear regression with partial correlations allowing to control for confounding effect from any variable on the others. All statistical analyses were performed using the Statistical Package for the Social Sciences 11.5 (SPSS Inc., Chicago, IL, USA). A P-value of,0.05 was considered significant. Results The menstrual status was used as an index of the severity of the FA. Therefore, the whole PCOS group was split into three subgroups according to the menstrual status, i.e. amenorrhoea, oligomenorrhoea or regular cycles, each including 63 (13.8%), 284 (62.1%) and 110 (24%) patients, respectively. 1563

Dewailly et al. Table 1 shows the median values with 5th 95th percentiles of the main clinical, hormonal and ultrasound parameters in controls and each PCOS subgroup. By the Mann Whitney test, the rank of values from every PCOS subgroup differed significantly from controls for all parameters, except for age in the regular cycle subgroup (P ¼ 0.054) and for the 6 9 mm FN in the amenorrhoeic subgroup (P ¼ 0.063). One-factor ANOVA displayed significant variations between PCOS subgroups for all variables except body mass index (P ¼ 0.063). The results of the 2 2 comparisons of PCOS subgroups after post hoc analysis with Bonferroni s correction are indicated in Table 1. Interestingly, the 2 5 and 6 9 mm FNs varied inversely according to the menstrual status (Fig. 1). After stepwise discriminant analysis, the 2 5 mm FN displayed the strongest association to the menstrual status (step 1: F to eliminate ¼ 12.63), followed by age (step 2: F to eliminate ¼ 6.31) and then by insulin (step 3: F to eliminate ¼ 5.33; F minimum to include ¼ 3.84). The other variables [waist circumference (WC), testosterone, FSH, LH and ovarian area] were rejected by the analysis. When the data were reanalysed by selecting the PCOS patients with a testosterone level. 0.5 ng/ml (n ¼ 139), the discriminant analysis selected only the 2 5 mm FN and rejected all the other variables. Multiple linear regression was performed in an attempt to explain the relationship between FA and the 2 5 mm FN. A significant and independent negative relationship was found between the 2 5 mm and 6 9 mm FN in the whole PCOS group (r ¼ 2 0.186, P, 0.01) (Fig. 2). The 2 5 mm FN was also negatively related to age and positively related to testosterone, independently from the other variables (r ¼ 2 0.104, P, 0.05 and r ¼ 0.154, P, 0.01, respectively). The 6 9 mm FN was negatively related to WC, independently from the 2 5 mm FN (r ¼ 20.108, P, 0.05). A similar significant and independent negative relationship between the 2 5 and 6 9 mm FN was found in controls (r ¼ 20.281, P, 0.01) (Fig. 2). In this group, the 2 5 mm FN was also significantly and negatively related to age independently from the other variables (r ¼ 20.238, P, 0.01). Discussion Multivariate analysis in our patients with PCOS showed that the 2 5 mm FN was associated very strongly with the severity of the menstrual disorder that we used as a marker of the FA. In our stepwise discriminant analysis, this relationship was the strongest (step 1) and it was independent from two other major determinants of the FA, namely age and fasting insulin level, that were also kept in the model (steps 2 and 3, respectively). Therefore, our data confirm the well-known improving effect of age (Elting et al., 2003) as well as the worsening effect of HI (Franks et al., 1998) on the FA of PCOS. In addition, it shows that the excess in 2 5 mm follicles is another independent and important contributor to the FA of PCOS. Putatively explaining such an effect, we observed an independent and strong negative relationship between the 2 5 and 6 9 mm FN, confirming our preliminary report (Jonard et al., 2003b). Interestingly, this relationship was also found in controls, as shown in Fig. 2, thus suggesting the presence of a physiological negative influence from the 2 5 mm follicle pool on the terminal follicle growth at the time of selection, independently from the intra- or extra-ovarian factors known to intervene in this process. Putatively, the larger the number of 2 5 mm follicles, the lower the proportion of them growing to 6 9 mm and further follicles. In the normal situation, such a regulation at the time of follicle selection for dominance would serve to prevent multiple ovulation. In PCOS, this natural phenomenon would be overdriven and would thus impair any follicle to become dominant. Among the factors that may drive this regulation, the anti-müllerian hormone (AMH) presents itself as a good candidate since its expression is maximal in granulosa cells of this follicle class (Weenen et al., 2004), where it inhibits FSH-induced effects such as aromatase expression (Durlinger et al., 2001). In patients with PCOS, there is a marked increase in the serum AMH level (Pigny et al., 2003; Laven et al., 2004) and we have shown previously (Pigny et al., 2003) that it is tightly related to the 2 5 mm FN but not to the 6 9 mm FN. In addition, we recently reported in a smaller series of patients Table 1: Median values with 5th 95th percentiles (in parenthesis) of the tested variables in PCOS and control groups PCOS (n ¼ 457) Amenorrhea (n ¼ 63) Oligomenorrhea (n ¼ 284) Regular cycles (n ¼ 110) Controls (n ¼ 188) Age (years) 26.0 (17.2 36.2) a,b 28.0 (20.0 35.5) 28.0 (21.4 35.2) 29.0 (22.4 36.0) BMI (kg/m 2 ) 28.2 (19.4 42.5) 25.2 (18.8 41.9) 24.6 (18.4 39.9) 22.9 (18.1 35.0) WC (cm) 90.0 (64.0 123.0) b 82.0 (64.3 117.7) 80.0 (62.5 113.5) 73.0 (60.0 102.2) Testosterone (ng/ml) 0.58 (0.28 1.16) a,b 0.46 (0.13.92) c 0.38 (0.16.75) 0.25 (0.08.54) LH (IU/l) 6.8 (2.2 17.5) 6.2 (2.1 14.8) 4.9 (1.8 13.8) 3.9 (2.0 7.3) FSH (IU/l) 4.8 (2.8 7.1) 5.2 (3.3 7.7) 5.3 (3.9 7.9) 5.9 (4.3 8.5) Insulin (miu/l) 7.8 (1.2 34.4) a,b 5.2 (1.0 20.3) 4.4 (0.9 15.3) 3.4 (0.9 10.1) 2 5 mm FN 17.5 (6.6 40.2) a,b 13.5 (4.0 28.4) c 11.5 (3.7 24.6) 4.5 (2.2 9.5) 6 9 mm FN 1.5 (0 10.0) a,b 3.5 (0 12.0) 4.0 (0 12.2) 2.3 (0 5.5) Ovarian area (cm 2 ) 6.68 (3.9 9.3) a,b 5.9 (3.8 8.6) c 5.47 (3.7 7.4) 3.9 (2.8 5.1) a Amenorrhoea subgroup significantly different from oligomenorrhoea subgroup (ANOVA with post hoc analysis, P, 0.05). b Amenorrhoea subgroup significantly different from regular cycle subgroup (ANOVA with post hoc analysis, P, 0.05). c Oligomenorrhoea subgroup significantly different from regular cycle subgroup (ANOVA with post hoc analysis, P, 0.05); See Results for the comparisons between controls and each PCOS subgroup. 1564

Follicle excess and follicular arrest in PCOS that serum AMH level was closely related to the severity of the menstrual disorder, along with the 2 5 mm FN (Pigny et al., 2006). We hypothesize, therefore, that in PCO the excess of small antral follicles would create an exaggerated AMH tone within the microenvironment of the selectable follicles. This would impair the action of FSH and would thus contribute to Figure 2: Negative relationship between the 2 5 and 6 9 mm FN in controls (n ¼ 188) and in patients with PCOS (n ¼ 457). The upper and lower regression lines apply to the PCOS and control group, respectively. See the text for the values of the correlation coefficients. the aromatase inhibition that characterizes the FA of PCOS (Jakimiuk et al., 1997). However, we recognize that this assumption is based on correlation data that do not imply causality. Surprisingly, serum testosterone was not retained by the stepwise discriminant analysis as a variable contributing to the FA. This disagrees at first sight with many previous reports establishing a link between HA and OA in patients with PCOS (reviewed in Diamanti-Kandarakis et al., 2006). However, the explanation may reside in the fact that HA would contribute to FA via the 2 5 mm follicle excess that it favours (Vendola et al., 1998; Weil et al., 1998). Therefore, this variable did not contribute enough by itself in our stepwise discriminant analysis when challenged to stronger variables such as the 2 5 mm FN. In addition, we recently reported that this link is not constant since some patients with PCO are oligomenorrhoeic despite the absence of overt HA (Dewailly et al., 2006). Conversely, other patients with HA and PCO are eumenorrhoeic (Carmina and Lobo 2001). Altogether, these observations may indicate that in many situations the peripheral androgenic status poorly reflects the intra-ovarian androgen effects. However, the fact that only the 2 5 mm FN was selected after including only those PCOS patients with a testosterone level. 0.5 ng/ml strengthens our conclusion that HA influences the menstrual cycle abnormalities through its effect on the follicle excess in PCOS. In the more frankly hyperandrogenic patients, this 1565 Figure 1: Box-and-whisker plots showing the distribution of individual values for 2 5 (left) and 6 9 mm (right) FN in patients with PCOS, according to their menstrual status. Horizontal small bars represent the 5th 95th percentile range, and the boxes indicate the 25th 75th percentile range. The horizontal line in each box corresponds to the median. Open circles represents values beyond the 95th percentile. See Table 1 for comparisons between groups.

Dewailly et al. relationship overcomes the ones involving age or HI. Lastly, that serum LH and FSH were not retained by the analysis fits with the current opinion that the FA of PCOS is mainly driven by intra-ovarian abnormalities and that the gonadotropin derangement is secondary (Franks et al., 1998). In this study, the independent relationship between FA and insulin confirms the worsening effect of HI and/or IR on the FA of PCOS (Franks et al., 1998). This effect does not seem to act through amplification of the negative effect exerted by the excess of 2 5 mm follicles. Rather, it would be additive through different mechanisms, as suggested in this study by the inverse relationship between the 6 9 mm FN and the WC, independently from the 2 5 mm FN. Since WC is strongly associated to HI and/or IR, this finding is also in line with numerous reports about the negative effect of the metabolic component of PCOS on the ovulatory status (reviewed in Pasquali et al., 2006). Further to a quantitative effect (i.e. reduced proportion of 6 9 mm follicles), this metabolic influence may also exert a qualitative derangement of granulosa cells, as suggested by an insufficient production of inhibins at that follicle stage in PCO (Welt et al., 2005). This could explain why in our study patients were amenorrhoeic or oligomenorrhoeic despite the presence of an absolute number of 6 9 mm follicles that was normal or greater than controls, respectively. To conclude, this study shows that the size of the 2 5 mm follicle pool has a very strong and specific impact on the FA of PCOS. We propose the hypothesis of an autoinhibiting effect within the selectable follicle pool that exists in normal women but is exaggerated in PCOS. However, further research is warranted to support this hypothesis and clearly, more experimental data are needed in humans to elucidate which factor(s) is involved in this inhibition. Acknowledgements We thank Mrs Francine Becquin for her excellent technical help, Ms Sophie Delva, Céline Vandaele and Claire Vandamme for collecting the clinical data and Mrs Lydie Lombardo and Sylvie Vanoverschelde for collecting the blood samples. We thank Dr Patrick Devos, Centre d études et de Recherches en Informatique Médicale, University of Lille 2, for his help in the Statistics. References Carmina E, Lobo RA. Polycystic ovaries in hirsute women with normal menses. Am J Med 2001;111:602 606. Dewailly D, Catteau-Jonard S, Reyss AC et al. Oligo-anovulation with Polycystic Ovaries (PCO) but not overt hyperandrogenism. J Clin Endocrinol Metab 2006; Jul 18; [Epub ahead of print]. Dewailly D, Cortet-Rudelli C, Decanter C. The polycystic ovary syndrome: reproductive aspects. In: Wass JAH, Shalet SM (eds). The Oxford Textbook of Endocrinology. Oxford, UK, Oxford University Press: 2003, 1135 1143. Diamanti-Kandarakis E, Papailiou J, Palimeri S. Hyperandrogenemia: pathophysiology and its role in ovulatory dysfunction in PCOS. Pediatr Endocrinol Rev 2006;3(Suppl. 1): 198 204. Durlinger AL, Gruijters MJ, Kramer P et al. Anti-Müllerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology 2001;142:4891 4899. Elting MW, Kwee J, Korsen TJM et al. Aging women with polycystic ovary syndrome who achieve regular menstrual cycles have a smaller follicle cohort than those who continue to have irregular cycles. Fertil Steril 2003;79:1154 1160. Franks S. Assessment and management of anovulatory infertility in polycystic ovary syndrome. Endocrinol Metab Clin North Am 2003;32:639 651. Franks S, Mason H, White D et al. Etiology of anovulation in polycystic ovary syndrome. Steroids 1998;63:306 307. Hughesdon PE. Morphology and morphogenesis of the Stein-Leventhal ovary and of so-called hyperthecosis. Obstet Gynecol Surv 1982;37:59 77. Jakimiuk AJ, Jakowicki JA, Magoffin DA. Follicular development in polycystic ovary syndrome. Assist Reprod Rev 1997;7:54 57. Jonard S, Dewailly D. The follicular excess in polycystic ovaries due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum Reprod Update 2004;2:1 11. Jonard S, Dewailly D, Pigny P et al. What are the determinants of the antral follicle number at ovarian ultrasonography (U/S) in PCOS? ESHRE Congress, Madrid, 29 June to 3 July 2003, oral communication, #0-119. Hum Reprod 2003b;18(Suppl 1): 42. Jonard S, Robert Y, Cortet-Rudelli C et al. Ultrasound examination of polycystic ovaries: is it worth counting the follicles? Hum Reprod 2003a;18:598 603. Laven JSE, Mulders AGMGJ, Visser JA et al. AMH serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 2004;89:318 323. Pasquali R, Gambineri A, Pagotto U. The impact of obesity on reproduction in women with polycystic ovary syndrome. BJOG 2006; Jul 7; [Epub ahead of print]. Pigny P, Jonard S, Robert Y et al. Serum anti-mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:941 945. Pigny P, Merlen E, Robert Y et al. Elevated serum level of AMH in patients with PCOS: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab 2003;88:5957 5962. The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41 47. Vendola KA, Zhou J, Adesanya OO et al. Androgens stimulate early stages of follicular growth in the primate ovary. J Clin Invest 1998;101:2622 2629. Webber LJ, Stubbs S, Stark J et al. Formation and early development of follicles in the polycystic ovary. Lancet 2003;362:1017 1021. Weenen C, von Bergh ARM, Cranfield M et al. Anti-Müllerian Hormone (AMH) expression pattern in the Human Ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 2004;10:77 83. Weil SJ, Vendola K, Zhou J et al. Androgen receptor gene expression in the primate ovary: cellular localization, regulation, and functional correlations. J Clin Endocrinol Metab 1998;83:2479 2485. Welt CK, Taylor AE, Fox J et al. Follicular arrest in polycystic ovary syndrome is associated with deficient inhibin A and B biosynthesis. J Clin Endocrinol Metab 2005;90:5582 5587. Submitted on December 4, 2006; resubmitted on February 7, 2007; accepted on February 13, 2007 1566